Boiron Laboratories first half 2024 sales and results

Laboratoires BOIRON has published its results for the first half of 2024. Sales amounted to 228.3 million euros, down 4.8% compared to the same period in 2023. This decrease is mainly due to a drop in sales in France and Europe outside France, despite an increase in sales in North America.

Operating profit fell by 72.6% to EUR 4.8 million. The decline in sales of homeopathic medicines, combined with an increase in operating costs, impacted the gross margin. Net investments and net cash also decreased, by 24.8% and 78.7% respectively.

Net income attributable to the Group amounted to 3.3 million euros, representing a decrease of 78.5%. This decrease is partly due to a decrease in investment income. Reorganization costs in France totaled 3 million euros for the half-year.

The company is exploring positive outlook for the end of the year, speculating on the level of seasonal pathologies to influence sales. BOIRON continues to be committed to promoting homeopathy and other health solutions globally.